Abstract
Depression is an affective disorder characterized by hallucination, delusion and increased social risk and is estimated to affect approximately 20 % of the population at some point during the lifetime. As per World Health Organization (WHO) it is predicted to be the leading cause of burden of disease by 2030. Effects of currently available antidepressants have explained the monoamine hypothesis of depression, which proposes that impaired release of serotonin, noradrenaline and dopamine, are thought to be responsible for the development of depressive symptoms. However, these drugs are not specific for their action, as they also inhibit other enzymes; this explains the side effects/drug interactions associated with these agents. The present review will familiarize the readers with novel targets being identified for depression which will be certainly beneficial for researcher, academician for the development of drugs for the management of depression and related behavior.
Keywords: Cholinergic receptors, cocaine and amphetamine regulated transcript peptide, depression, histaminergic receptors, N-methyl-D-aspartate, oxidative stress, substance P.
CNS & Neurological Disorders - Drug Targets
Title:Potential Targets for the Development of Novel Antidepressants: Future Perspectives
Volume: 14 Issue: 2
Author(s): Vishnu N. Thakare and Bhoomika M. Patel
Affiliation:
Keywords: Cholinergic receptors, cocaine and amphetamine regulated transcript peptide, depression, histaminergic receptors, N-methyl-D-aspartate, oxidative stress, substance P.
Abstract: Depression is an affective disorder characterized by hallucination, delusion and increased social risk and is estimated to affect approximately 20 % of the population at some point during the lifetime. As per World Health Organization (WHO) it is predicted to be the leading cause of burden of disease by 2030. Effects of currently available antidepressants have explained the monoamine hypothesis of depression, which proposes that impaired release of serotonin, noradrenaline and dopamine, are thought to be responsible for the development of depressive symptoms. However, these drugs are not specific for their action, as they also inhibit other enzymes; this explains the side effects/drug interactions associated with these agents. The present review will familiarize the readers with novel targets being identified for depression which will be certainly beneficial for researcher, academician for the development of drugs for the management of depression and related behavior.
Export Options
About this article
Cite this article as:
Thakare N. Vishnu and Patel M. Bhoomika, Potential Targets for the Development of Novel Antidepressants: Future Perspectives, CNS & Neurological Disorders - Drug Targets 2015; 14 (2) . https://dx.doi.org/10.2174/1871527313666140806121648
DOI https://dx.doi.org/10.2174/1871527313666140806121648 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis
Current Alzheimer Research Ganglioside GM3 and Its Role in Cancer
Current Medicinal Chemistry Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets LHON: Mitochondrial Mutations and More
Current Genomics Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Prion Protein Oligomerization
Current Alzheimer Research Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets High-Throughput Screening Technologies for Botulinum Neurotoxins
Current Topics in Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry APP-Based Neuroprotective Strategies
Current Alzheimer Research